engleski

CYP2D6 polymorphism in patients with head and neck cancer

We investigated the association of drug metabolizing enzyme system CYP P450 CYP2D6 null alleles (CYP2D6*3, *4, *5, *6, *7, and *8) with incidence of tumors in patients having head and neck cancer (HNC). It is known that persons bearing two null alleles poorly metabolize some common drugs (Poor Metabolizer phenotype – PM) as well as other xenobiotic and carcinogenic substances. Persons with only one disrupted CYP2D6 gene (bearing one normal and one null allele) are considered to be Intermediate Metabolizer phenotype (IM). We genotyped 145 controls, and 67 HNC patients by Multiplex Allele Specific PCR on whole blood DNA. Study results showed allelic frequencies for *3, *4 and *6 alleles (only alleles observed) in controls to be 1.4%, 11.0% and 1.0%, respectively; among them we found 2.1% PMs and 22.8% IMs. In cancer patient’s group allelic frequencies for *3, *4 and *6 were 1.5%, 19.4% and 3,7% respectively, and no other alleles were found; among them we found 3.0% PMs and 43.3% IMs. Our study results showed statistically significant difference for genotype frequencies (Chi-square; p=0.025) as well as predicted phenotype frequencies (Chi-square; p=0.034). IM phenotype showed to be responsible for increased risk to HNC (Odds ratio 2.6; 95%CI= 1.248 - 5.193). To confirm our preliminary findings, we plan to study larger group of patients.

CYP2D6; head and neck cancer

nije evidentirano